Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin vs Sitagliptin in T2DM and Heart Failure (MEASURE-HF)
NCT02917031Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, double-blind trial of saxagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Left Ventricular End Diastolic Volume Index at 24 weeks. Started Jan 2017; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02917031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917031.